Logo image of CTXR

CITIUS PHARMACEUTICALS INC (CTXR) Stock Fundamental Analysis

NASDAQ:CTXR - Nasdaq - US17322U3068 - Common Stock - Currency: USD

1.595  +0.1 (+7.05%)

After market: 1.6 +0.01 (+0.31%)

Fundamental Rating

2

Taking everything into account, CTXR scores 2 out of 10 in our fundamental rating. CTXR was compared to 193 industry peers in the Pharmaceuticals industry. The financial health of CTXR is average, but there are quite some concerns on its profitability. CTXR has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CTXR had negative earnings in the past year.
CTXR had a negative operating cash flow in the past year.
In the past 5 years CTXR always reported negative net income.
In the past 5 years CTXR always reported negative operating cash flow.
CTXR Yearly Net Income VS EBIT VS OCF VS FCFCTXR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

CTXR has a Return On Assets (-35.48%) which is in line with its industry peers.
CTXR has a Return On Equity (-71.05%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -35.48%
ROE -71.05%
ROIC N/A
ROA(3y)-32.16%
ROA(5y)-30.75%
ROE(3y)-42.39%
ROE(5y)-39.56%
ROIC(3y)N/A
ROIC(5y)N/A
CTXR Yearly ROA, ROE, ROICCTXR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400

1.3 Margins

CTXR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTXR Yearly Profit, Operating, Gross MarginsCTXR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for CTXR has been increased compared to 1 year ago.
CTXR has less shares outstanding than it did 5 years ago.
CTXR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CTXR Yearly Shares OutstandingCTXR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
CTXR Yearly Total Debt VS Total AssetsCTXR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

Based on the Altman-Z score of -3.87, we must say that CTXR is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -3.87, CTXR is not doing good in the industry: 60.10% of the companies in the same industry are doing better.
CTXR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.87
ROIC/WACCN/A
WACCN/A
CTXR Yearly LT Debt VS Equity VS FCFCTXR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

CTXR has a Current Ratio of 0.37. This is a bad value and indicates that CTXR is not financially healthy enough and could expect problems in meeting its short term obligations.
CTXR has a worse Current ratio (0.37) than 94.82% of its industry peers.
CTXR has a Quick Ratio of 0.37. This is a bad value and indicates that CTXR is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of CTXR (0.06) is worse than 96.89% of its industry peers.
Industry RankSector Rank
Current Ratio 0.37
Quick Ratio 0.06
CTXR Yearly Current Assets VS Current LiabilitesCTXR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for CTXR have decreased strongly by -290.48% in the last year.
EPS 1Y (TTM)-290.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 22.18% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y24.46%
EPS Next 2Y52.19%
EPS Next 3Y39.28%
EPS Next 5Y22.18%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CTXR Yearly Revenue VS EstimatesCTXR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
CTXR Yearly EPS VS EstimatesCTXR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30 -40

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

CTXR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 1.15, the valuation of CTXR can be described as very cheap.
Based on the Price/Forward Earnings ratio, CTXR is valued cheaper than 100.00% of the companies in the same industry.
CTXR is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.52, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 1.15
CTXR Price Earnings VS Forward Price EarningsCTXR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTXR Per share dataCTXR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CTXR's earnings are expected to grow with 39.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.19%
EPS Next 3Y39.28%

More info and screens

0

5. Dividend

5.1 Amount

CTXR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CITIUS PHARMACEUTICALS INC

NASDAQ:CTXR (7/17/2025, 8:14:29 PM)

After market: 1.6 +0.01 (+0.31%)

1.595

+0.1 (+7.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-11 2025-08-11
Inst Owners6.17%
Inst Owner Change0%
Ins Owners4.79%
Ins Owner Change0%
Market Cap17.82M
Analysts80
Price Target5.78 (262.38%)
Short Float %9.08%
Short Ratio0.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1789.22%
Min EPS beat(2)-3457.42%
Max EPS beat(2)-121.01%
EPS beat(4)0
Avg EPS beat(4)-900.03%
Min EPS beat(4)-3457.42%
Max EPS beat(4)-4.05%
EPS beat(8)1
Avg EPS beat(8)-503.27%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-33.33%
EPS NQ rev (1m)3.31%
EPS NQ rev (3m)17.22%
EPS NY rev (1m)-386.57%
EPS NY rev (3m)-79.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)9.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)11.92%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.15
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.29
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.66
EYN/A
EPS(NY)1.39
Fwd EY87.29%
FCF(TTM)-2.56
FCFYN/A
OCF(TTM)-2.11
OCFYN/A
SpS0
BVpS5.43
TBVpS-3.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.48%
ROE -71.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.16%
ROA(5y)-30.75%
ROE(3y)-42.39%
ROE(5y)-39.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.37
Quick Ratio 0.06
Altman-Z -3.87
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-290.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.6%
EPS Next Y24.46%
EPS Next 2Y52.19%
EPS Next 3Y39.28%
EPS Next 5Y22.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-9.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-6.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.88%
OCF growth 3YN/A
OCF growth 5YN/A